ACHE and schistosomiasis: A recent schistosome protein microarray study showed a predicted S. japonicum AChE precursor (AY810792) was significantly targeted by protective IgG1 immune responses in S. haematobium-exposed individuals that had acquired drug-induced resistance to schistosomiasis after PZQ treatment [17], thereby supporting consideration of AChE as a suitable antischistosomiasis vaccine candidate.